Cdk inhibitors in development and cancer

被引：2
|
作者：
Harper, JW
Elledge, SJ
机构：
[1] BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030
[2] BAYLOR COLL MED,DEPT BIOCHEM,HOUSTON,TX 77030
来源：
CURRENT OPINION IN GENETICS & DEVELOPMENT | 1996年 / 6卷 / 01期
关键词：
D O I：
暂无
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
Activation of cyclin-dependent kinases is the primary control point of cell proliferation. Recent advances in the understanding of cell-cycle regulation have uncovered two families of proteins that bind and inhibit these kinases. These proteins are likely mediators of development and differentiation, and may provide molecular connections between the pathways of development and tumorigenesis.
引用
下载
收藏
页码：56 / 64
页数：9
相关论文
共 50 条
  • [41] CDK4/6 inhibitors in luminal breast cancer
    Gnant, Michael
    Steger, Guenther G.
    Bartsch, Rupert
    LANCET ONCOLOGY, 2015, 16 (01): : 2 - 3
  • [42] ATP-noncompetitive CDK inhibitors for cancer therapy: an overview
    Abate, Agnese Anna
    Pentimalli, Francesca
    Esposito, Luca
    Giordano, Antonio
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (07) : 895 - 906
  • [43] The Role of CDK 4/6 Inhibitors in Breast Cancer Treatment
    Bartsch, Rupert
    Fitzal, Florian
    Hubalek, Michael
    Knauer, Michael
    Untch, Michael
    BREAST CARE, 2015, 10 (05) : 340 - 343
  • [44] Purine CDK inhibitors
    Lloyd, AW
    DRUG DISCOVERY TODAY, 1999, 4 (10) : 482 - 482
  • [45] Global Trend in Research and Development of CDK4/6 Inhibitors for Clinical Cancer Therapy: A Bibliometric Analysis
    Lai, Hongna
    Jiang, Wei
    Zhao, Jianli
    Dinglin, Xiaoxiao
    Li, Yudong
    Li, Shunying
    Wang, Ying
    Yao, Herui
    JOURNAL OF CANCER, 2021, 12 (12): : 3539 - 3547
  • [46] Development of personalized medicine for breast cancer based on elucidation of resistance mechanisms to CDK4/6 inhibitors
    Kobayashi, Yoshie
    Motoi, Yusuke
    Fujimoto, Mutsumi
    Shigematsu, Hideo
    CANCER RESEARCH, 2023, 83 (05)
  • [47] CDK6 overexpression promotes resistance to CDK4/6 inhibitors in breast cancer
    Li, Qing
    Razavi, Pedram
    Li, Zhiqiang
    Paula, Arnaud F. Da Cruz
    Brogi, Edi
    Scaltriti, Maurizio
    Reis-Filho, Jorge S.
    Chandarlapaty, Sarat
    CANCER RESEARCH, 2019, 79 (13)
  • [48] Development of CDK4/6 Inhibitors: A Five Years Update
    Ammazzalorso, Alessandra
    Agamennone, Mariangela
    De Filippis, Barbara
    Fantacuzzi, Marialuigia
    MOLECULES, 2021, 26 (05):
  • [49] Development of an assay to screen for inhibitors of tau phosphorylation by cdk5
    Ahn, JS
    Musacchio, A
    Mapelli, M
    Ni, J
    Scinto, L
    Stein, R
    Kosik, KS
    Yeh, LA
    JOURNAL OF BIOMOLECULAR SCREENING, 2004, 9 (02) : 122 - 131
  • [50] CDK inhibitors from past to present: A new wave of cancer therapy
    Mughal, Muhammad Jameel
    Bhadresha, Kinjal
    Kwok, Hang Fai
    SEMINARS IN CANCER BIOLOGY, 2023, 88 : 106 - 122
12345